NADK Gene

NADK Gene

NADK Gene

<div class="infobox infobox-gene">
<div class="infobox-header">NADK</div>

Overview

NADK is a human gene whose product NADK encodes NAD kinase, the enzyme that catalyzes NADP+ biosynthesis from NAD+. It is the first and rate-limiting step in NADP+ production.[@nad2015] NADK variants have been implicated in Alzheimer's Disease and Parkinson's Disease.[@sorbi2022] This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.

NADK Gene

NADK Gene

<div class="infobox infobox-gene">
<div class="infobox-header">NADK</div>

Overview

NADK is a human gene whose product NADK encodes NAD kinase, the enzyme that catalyzes NADP+ biosynthesis from NAD+. It is the first and rate-limiting step in NADP+ production.[@nad2015] NADK variants have been implicated in Alzheimer's Disease and Parkinson's Disease.[@sorbi2022] This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.

<div class="infobox-row"><span class="infobox-label">Full Name</span><span class="infobox-value">NAD Kinase</span></div>
<div class="infobox-row"><span class="infobox-label">Symbol</span><span class="infobox-value">NADK</span></div>
<div class="infobox-row"><span class="infobox-label">Chromosomal Location</span><span class="infobox-value">1p36.23</span></div>
<div class="infobox-row"><span class="infobox-label">NCBI Gene ID</span><span class="infobox-value">[55712](https://www.ncbi.nlm.nih.gov/gene/55712)</span></div>
<div class="infobox-row"><span class="infobox-label">OMIM</span><span class="infobox-value">[607785](https://www.omim.org/entry/607785)</span></div>
<div class="infobox-row"><span class="infobox-label">Ensembl ID</span><span class="infobox-value">ENSG00000008130</span></div>
<div class="infobox-row"><span class="infobox-label">UniProt ID</span><span class="infobox-value">[Q9P2R7](https://www.uniprot.org/uniprot/Q9P2R7)</span></div>
<div class="infobox-row"><span class="infobox-label">Associated Diseases</span><span class="infobox-value">[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease)</span></div>
</div>

Function

NADK encodes NAD kinase, the enzyme that catalyzes NADP+ biosynthesis from NAD+. It is the first and rate-limiting step in NADP+ production [1](https://doi.org/10.1016/j.tibs.2015.08.001). This enzyme plays a critical role in maintaining cellular redox balance and supporting biosynthetic pathways essential for neuronal survival and function.

Catalytic Mechanism

NADK catalyzes the phosphorylation of NAD+ to produce NADP+:

NAD+ + ATP → NADP+ + ADP

This reaction requires magnesium ion (Mg2+) as a cofactor and represents the sole known enzymatic pathway for de novo NADP+ synthesis in mammalian cells. The enzyme exhibits Michaelis-Menten kinetics with a Km for NAD+ of approximately 0.1-0.5 mM and a Vmax that varies with tissue type and metabolic state [1].

NAD(P)+ Metabolism

NADK is essential for maintaining NADP+ levels, which serve multiple critical cellular functions [1][4]:

NADPH Production:

• Antioxidant defense: NADPH provides reducing equivalents for glutathione reductase and NADPH oxidase
• Biosynthetic reactions: Fatty acid synthesis, cholesterol synthesis, and nucleotide synthesis require NADPH
• DNA repair: PARP activity consumes NAD+, and NADPH supports repair processes
• Immune response: NADPH oxidase in phagocytic cells generates reactive oxygen species for microbial killing

• Counteracting oxidative stress in neurons, which are particularly vulnerable to reactive oxygen species due to high metabolic demand
• Maintaining the reduced glutathione pool essential for detoxification
• Supporting mitochondrial function and ATP production

Role in Neurodegeneration

NADK is crucial for neuronal health through multiple mechanisms [2][3][5][6]:

Alzheimer's Disease:
NADK activity declines in AD brains, reducing NADPH and increasing oxidative stress [2](https://doi.org/10.1016/j.nbd.2018.03.014). Research has demonstrated:

• Reduced NADK protein expression and activity in prefrontal cortex and hippocampus of AD patients [7]
• Decreased NADP+/NADPH ratio correlates with disease severity
• NADK reduction contributes to impaired antioxidant defense and increased amyloid-beta toxicity [16]
• Tau pathology may directly or indirectly affect NADK function [17]

• 6-OHDA and MPTP toxicity is attenuated by NADK overexpression
• NADK maintains glutathione levels essential for dopaminergic neuron survival
• Mitochondrial complex I inhibition in PD may involve NADK dysregulation
• α-Synuclein aggregation affects NADK activity

• Age-related decline in NADK contributes to metabolic inflexibility
• Reduced NADP+ impairs stress response mechanisms
• Caloric restriction partially reverses age-related NADK decline

Disease Associations

Alzheimer's Disease

NADK dysfunction contributes to AD through multiple interconnected pathways [2][7][16][17]:

Mechanisms:

• Reduced NADPH → impaired antioxidant defense
• Increased oxidative stress and lipid peroxidation
• Impaired DNA repair via PARP inhibition
• Mitochondrial dysfunction and energy deficit
• Accelerated amyloid-beta aggregation
• Tau hyperphosphorylation and neurofibrillary tangle formation

• NADK activators may restore NADP+ levels in AD brain
• Combined NAD+ and NADK boosting strategies being explored
• Gene therapy approaches to increase NADK expression

Parkinson's Disease

In PD, NADK provides neuroprotection through several mechanisms [3][8][9]:

Dopaminergic Neuron Protection:

• Protection against 6-OHDA and MPTP toxicity
• Maintenance of glutathione levels
• Support of mitochondrial function and ATP production
• Preservation of dopaminergic neuron-specific signaling

• NADK supports mitophagy through NADP+-dependent pathways
• Protects against mitochondrial DNA damage
• Maintains mitochondrial membrane potential

• Small molecule NADK activators in development [19]
• AAV-mediated NADK gene delivery being investigated
• Combination approaches with NAD+ precursors

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS):

• NADK activity reduced in motor neurons of ALS patients
• SOD1 mutant toxicity exacerbated by NADK deficiency
• Therapeutic targeting under investigation

• Hyperglycemia-induced NADK impairment
• Oxidative stress accumulation
• Polyol pathway hyperactivity

• NADK supports neuronal energy homeostasis
• Mutant huntingtin affects NADK function
• NADP+ supplementation may be beneficial

Expression

Tissue Distribution

NADK is ubiquitously expressed with highest levels in tissues with high metabolic activity [1]:

| Tissue | Expression Level |
|--------|-----------------|
| Brain | High (cortex, hippocampus) |
| Liver | Very High |
| Heart | High |
| Skeletal muscle | High |
| Kidney | Moderate |
| Lung | Moderate |
| Pancreas | Moderate |

Brain Region Specificity

Within the brain, NADK shows region-specific expression [5]:

• Cortex: Highest in pyramidal neurons of layers 2-6
• Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
• Substantia nigra: Dopaminergic neurons
• Cerebellum: Purkinje cells
• Brainstem: Motor and sensory nuclei

Cellular Localization

NADK localizes primarily to the cytosol, with some association with:

• Mitochondrial outer membrane
• Nuclear envelope
• Endoplasmic reticulum

Developmental Regulation

NADK expression is developmentally regulated:

• Low expression during embryonic development
• Increases postnatally with neuronal maturation
• Highest expression in adult brain
• Declines with age in multiple brain regions

Molecular Mechanisms

Regulation of NADK Activity

NADK activity is regulated at multiple levels:

Transcriptional Regulation:

• p53 directly activates NADK transcription
• c-Myc promotes NADK expression
• SIRT1 deacetylase modulates NADK gene expression
• Circadian clock genes regulate NADK rhythms

• Phosphorylation by PKC and PKA
• Acetylation by p300/CBP
• Ubiquitination and proteasomal degradation
• Sumoylation under stress conditions

• ATP concentration affects activity
• NAD+ and NADP+ feedback inhibition
• Magnesium ion requirement

NADK Signaling Pathways

NADK integrates with multiple signaling pathways:

Calcineurin-NFAT → NADK transcription
↓
AMPK → NADK activation (energy sensing)
↓
p53 → NADK activation (stress response)
↓
SIRT1 → NADK regulation (metabolism)

Key Interactions:

• AMPK activation increases NADK activity
• p53 tumor suppressor activates NADK
• SIRT1 deacetylates and activates NADK
• mTORC1 represses NADK expression

Therapeutic Implications

Targeting NADK in Neurodegeneration

Modulating NADK activity represents a promising therapeutic strategy [6][10][19][21]:

Activation Strategies:

Combination Approaches:

• NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) with NADK activators
• Antioxidant therapy combined with NADK boosting
• Mitochondrial protectants with NADK modulators

Challenges

• Blood-brain barrier penetration of small molecules
• Tissue-specific delivery
• Dose optimization
• Long-term safety concerns
• Patient stratification based on NADK activity

Biomarker Potential

NADK expression and activity may serve as biomarkers [15][18]:

• NADK levels in cerebrospinal fluid
• NADP+/NADPH ratio as metabolic marker
• Genetic variants affecting treatment response
• Expression changes correlating with disease progression

Animal Models

Knockout Studies

NADK knockout mice have been generated and exhibit:

• Embryonic lethality: Complete knockout is embryonic lethal
• Conditional knockouts: Tissue-specific deletion reveals essential functions
• Brain-specific knockout: Severe neurodegeneration phenotype
• Mitochondrial dysfunction: Impaired oxidative phosphorylation

Transgenic Models

NADK overexpression studies demonstrate:

• Neuroprotection: Resistance to various toxic insults
• Enhanced antioxidant capacity: Improved glutathione maintenance
• Improved mitochondrial function: Better energy metabolism
• Extended neuronal survival: In various disease models

Disease Models

In various neurodegenerative disease models:

• AD models: Reduced amyloid-beta and tau pathology with NADK overexpression
• PD models: Protected dopaminergic neurons
• ALS models: Improved motor neuron survival
• Aging models: Reduced age-related cognitive decline

Protein Interactions

Direct Binding Partners

| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|------------------------|
| p53 | Transcriptional activation | Cell cycle and stress response |
| AMPK | Phosphorylation | Energy sensing |
| SIRT1 | Deacetylation | Metabolic regulation |
| PKC | Phosphorylation | Signal transduction |
| Mitochondrial proteins | Physical association | Energy metabolism |

Signaling Network

NADK interacts with cellular networks:

• Metabolic pathways: Central carbon metabolism
• Antioxidant systems: Glutathione and thioredoxin
• DNA repair: PARP and SIRT1 pathways
• Mitochondrial function: TCA cycle and ETC

NADK Enzyme Structure

Protein Domains

NADK contains several functional domains:

Structural Studies

Crystal structures have revealed:

• Open and closed conformations
• Substrate-induced conformational changes
• Dimer interface formation
• Allosteric binding sites

Evolutionary Conservation

Species Conservation

NADK is evolutionarily conserved:

• Bacteria: Primarily NAD-dependent
• Yeast: Both NAD and NADP kinases
• Mammals: Dedicated NADK enzyme
• Plants: Multiple NADK isoforms

Functional Conservation

Across species:

• Catalytic mechanism is conserved
• Regulation differs by organism
• Subcellular localization varies
• Tissue distribution patterns differ

Clinical Perspectives

Diagnostic Applications

NADK as a biomarker:

• CSF NADK activity measurement
• Peripheral blood monocyte assessment
• Imaging-based detection approaches
• Genetic screening for variants

Therapeutic Development

Current pharmaceutical efforts:

• High-throughput screening for activators
• Structure-based drug design
• Prodrug approaches for brain delivery
• Gene therapy vector development

Pharmacological Strategies

Small Molecule Activators

Several classes of NADK activators are under development:

Direct Activators:

• Bind to allosteric sites on NADK
• Increase Vmax without affecting Km
• Subtype selectivity being optimized

• Increase NAD+ availability
• NAMPT activators to boost NMN
• NAD+ precursors combined with NADK activation

Drug Delivery Challenges

Blood-Brain Barrier (BBB):

• Molecular weight <400 Da preferred
• Lipophilicity for membrane passage
• Active transport systems being explored

• Measuring NADK activity in brain tissue
• PET tracers for NADK visualization
• Pharmacodynamic biomarkers

Clinical Trial Considerations

Patient Selection:

• Biomarker stratification
• Genotype-based enrollment
• Disease stage optimization

• NADP+/NADPH ratio in CSF
• Cognitive measures
• Imaging biomarkers
• Safety monitoring

Research Methods

Biochemical Approaches

Key experimental techniques:

• Enzyme activity assays
• NADP+/NADPH quantification
• Subcellular fractionation
• Protein interaction studies

Genetic Approaches

Research tools:

• CRISPR knockout and knockin
• siRNA and shRNA knockdown
• Transgenic and knockout mice
• Patient-derived iPSCs

Network Map

Genetic Variants

Known Polymorphisms

Several NADK variants have been associated with disease risk [9]:

• Missense variants: Altered enzymatic activity
• Regulatory variants: Changed expression levels
• Splice variants: Altered isoforms

Disease Associations

• Increased risk of late-onset AD
• Modifier of PD progression
• Variant modifying age of onset

Research Directions

Current Areas of Investigation

Future Perspectives

• Personalized medicine approaches based on NADK genotype
• Prevention strategies targeting NADK in at-risk individuals
• Biomarker development for patient selection
• Novel delivery systems for CNS targeting

Emerging Research Areas

Metabolomics Studies

Recent metabolomics approaches have revealed:

• NADP+ and NADPH levels as key metabolic indicators
• Correlation with disease severity in AD and PD
• Potential for diagnostic use

Systems Pharmacology

Computational approaches to NADK targeting:

• Network-based target identification
• Polypharmacology for combination therapy
• Patient-specific metabolic modeling

Translational Research

From bench to bedside:

• Preclinical validation of lead compounds
• IND-enabling studies
• Early-phase clinical trials

Summary

NADK (NAD Kinase) is a critical enzyme that catalyzes the rate-limiting step in NADP+ biosynthesis. Located at 1p36.23, this gene encodes a protein essential for maintaining cellular redox balance, supporting antioxidant defenses, and enabling biosynthetic pathways crucial for neuronal survival [1][6].

In neurodegeneration, NADK dysfunction plays a significant role:

• Alzheimer's Disease: NADK activity decline contributes to oxidative stress, impaired antioxidant defense, and accelerated pathology [2][7][16]
• Parkinson's Disease: NADK protects dopaminergic neurons from oxidative damage and mitochondrial toxins [3][8]
• Aging: NADK expression decreases with age, contributing to metabolic decline [4][18]

Key Takeaways

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [NAD+ metabolism pathway](/mechanisms/nad-metabolism)
• [Oxidative stress pathway](/mechanisms/oxidative-stress)
• [Neuroprotection strategies](/mechanisms/neuroprotection-pathways)
• [Mitochondrial function](/mechanisms/mitochondrial-dysfunction)
• [Mitochondrial function](/mechanisms/mitochondrial-dysfunction)

References